Home > Haematology > ASH 2019 > Inclusive Medicine > Mild renal impairment in African Americans does not affect OS in AML

Mild renal impairment in African Americans does not affect OS in AML

Presented By
Dr Abby Statler, Cleveland Clinic, USA
Conference
ASH 2019
Overall survival of acute myeloid leukaemia (AML) patients with mild renal dysfunction did not differ from patients with normal renal function. Given that African Americans in this study had significantly higher creatinine levels when compared with Caucasians, the investigators postulated that reduced renal function effectively selects against people of African descent to participate in clinical trials, even though survival is not affected. Dr Abby Statler (Cleveland Clinic, USA) and colleagues included 1,040 AML patients who received chemotherapy at Cleveland Clinic between 2003 and 2019 [1]. Approximately 10% of that cohort was African American, whereas 90% was Caucasian. Renal function was tested at every blood draw and assessed retrospectively for association with AML outcome. A total of 63% of African Americans with acute myeloid leukaemia (AML) presented with an abnormal renal function measurement, compared with 56% in the overall cohort (P=0....


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on